Search Results - "Freriks, Stephan"

  • Showing 1 - 5 results of 5
Refine Results
  1. 1

    Acquired and intrinsic resistance to vemurafenib in BRAFV600E‐driven melanoma brain metastases by Zhang, Ping, Kuil, Laura Esmee, Buil, Levi Conrad Maria, Freriks, Stephan, Beijnen, Jos Hendrik, Tellingen, Olaf, Gooijer, Mark Cornelis

    Published in FEBS open bio (01-01-2024)
    “…BRAFV600‐mutated melanoma brain metastases (MBMs) are responsive to BRAF inhibitors, but responses are generally less durable than those of extracranial…”
    Get full text
    Journal Article
  2. 2

    Abstract LB-255: Acquired and intrinsic resistance to vemurafenib in BRAFv600e-driven melanoma brain metastases by Gooijer, Mark C. de, Zhang, Ping, Buil, Levi C., Freriks, Stephan, Li, Gang, Beijnen, Jos H., Tellingen, Olaf Van

    Published in Cancer research (Chicago, Ill.) (01-07-2019)
    “…Purpose: BRAFV600-mutated melanoma brain metastases (MBMs) are generally responsive to BRAF and MEK inhibitors, albeit that responses are generally less…”
    Get full text
    Journal Article
  3. 3

    DDRE-01. ACQUIRED AND INTRINSIC RESISTANCE TO VEMURAFENIB IN BRAFV600E-DRIVEN MELANOMA BRAIN METASTASES by de Gooijer, Mark C, Zhang, Ping, Buil, Levi C M, Freriks, Stephan, Li, Gang, Beijnen, Jos H, van Tellingen, Olaf

    Published in Neuro-oncology (Charlottesville, Va.) (09-11-2020)
    “…BRAF V600-mutated melanoma brain metastases (MBMs) are responsive to BRAF inhibitors, but clinical responses are less durable than those of extracranial…”
    Get full text
    Journal Article
  4. 4

    Acquired and intrinsic resistance to vemurafenib in BRAF V600E -driven melanoma brain metastases by Zhang, Ping, Kuil, Laura Esmee, Buil, Levi Conrad Maria, Freriks, Stephan, Beijnen, Jos Hendrik, van Tellingen, Olaf, de Gooijer, Mark Cornelis

    Published in FEBS open bio (01-01-2024)
    “…BRAF -mutated melanoma brain metastases (MBMs) are responsive to BRAF inhibitors, but responses are generally less durable than those of extracranial…”
    Get full text
    Journal Article
  5. 5

    Abstract 736: Combining PD1- and CTLA4-inhibiting antibodies with cisplatin or PARP inhibition in an attempt to eradicate BRCA1-deficient mouse mammary tumors by Blatter, Sohvi, Guyader, Charlotte, Küçükosmanoğlu, Aslı, Freriks, Stephan, de Visser, Karin, Borst, Piet, Rottenberg, Sven

    Published in Cancer research (Chicago, Ill.) (01-08-2015)
    “…Solid tumors are usually not eradicated by conventional chemotherapy resulting in disease relapse and mortality. An intriguing example is BRCA-associated…”
    Get full text
    Journal Article